問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2252Cases

2017-01-22 - 2023-12-22

Phase III

Completed
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    Filgotinib (GS-6034) Filgotinib (GS-6034)

Participate Sites
8Sites

Terminated4Sites

Study ended1Sites

邱正堂
Linkou Chang Gung Medical Foundation

2017-01-20 - 2025-08-15

Phase III

Completed
A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412)

  • Condition/Disease

    Head and Neck Neoplasms

  • Test Drug

    Keytruda

Participate Sites
7Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

楊慕華
Taipei Veterans General Hospital

Division of Radiation Therapy

2017-01-17 - 2020-09-30

Phase III

Completed
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER

  • Condition/Disease

    Gastric Cancer,Gastroesophageal Junction Cancer

  • Test Drug

    Nivolumab/Ipilimumab/Oxaliplatin/Fluorouracil/Leucovorin/Capecitabine

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

洪逸平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-01-01 - 2028-12-31

Phase II

Active
A Phase II, Dose-randomization, Open-label Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy (OASES)

  • Condition/Disease

    Hepatocellular Carcinoma

  • Test Drug

    Para-Toluenesulfonamide (PTS)

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

2025-03-01 - 2032-12-31

Phase II

Active
An Open-label Extension Study to Evaluate Safety and Tolerability of Sotatercept (MK-7962) Administered Using a Weight-banded Approach in Participants With Pulmonary Arterial Hypertension (PAH) on Standard of Care

  • Condition/Disease

    Pulmonary Arterial Hypertension

  • Test Drug

    凍晶乾燥注射劑

Participate Sites
3Sites

Recruiting3Sites

2025-10-15 - 2032-12-31

Phase III

Active
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease

  • Condition/Disease

    Parkinson's Disease

  • Test Drug

    注射劑

Participate Sites
6Sites

Recruiting6Sites

2025-09-23 - 2028-02-13

Active
A Randomized, Double-Blind, Active-Controlled Multicenter Phase 2 Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg-Negative Adult Subjects With Chronic Hepatitis B Virus Infection (B-SUPREME)

  • Condition/Disease

    Chronic Hepatitis B Infection

  • Test Drug

    膜衣錠 膜衣錠

Participate Sites
8Sites

Recruiting8Sites

2025-08-20 - 2029-02-17

Phase III

Active
AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

  • Condition/Disease

    Carcinoma, Non-Small-Cell Lung (NSCLC)

  • Test Drug

    凍晶注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-09-01 - 2031-08-14

Phase I/II

Active
A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

  • Condition/Disease

    Advanced Lung Cancer

  • Test Drug

    靜脈輸注液 溶液用粉劑

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2029-07-16

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  • Condition/Disease

    Alzheimer Disease

  • Test Drug

    膠囊劑

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 226
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB